Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL)

Clinica Chimica Acta

Volumn 411, Issue 17-18, 2010, Pages 1335-1340

  Demacq, Caroline ^a   Vasconcellos, Vivian B ^a   Izidoro Toledo, Tatiane C ^a   da Silva Silveira, Vanessa ^a   Canalle, Renata ^a   Queiroz, Rosane Gomes de Paula ^a   Tone, Luiz Gonzaga ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute lymphoblastic leukemia (ALL); Angiogenesis; Endothelial nitric oxide synthase (NOS3); Pharmacogenetics; Polymorphism; Vascular endothelial growth factor (VEGF)

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; VASCULOTROPIN; NOS3 PROTEIN, HUMAN; PRIMER DNA; VASCULOTROPIN A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; NUCLEOTIDE SEQUENCE; RECURRENT DISEASE;

BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA PRIMERS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; NITRIC OXIDE SYNTHASE TYPE III; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954218908     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.05.025     Document Type: Article

References (44)

1. Folkman J. Tumor Angiogenesis in Women With Node-Positive Breast Cancer. Cancer J Sci Am 1995, 1:106.
2. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997, 150:815-821.
3. Keyhani A., Jendiroba D.B., Freireich E.J. Angiogenesis and leukemia. Leuk Res 2001, 25:639-645.
4. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240-2245.
5. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
6. Aguayo A., Giles F., Albitar M. Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 2003, 44:213-222.
7. Podar K., Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
8. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
9. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684.
10. Ferrante M., Pierik M., Henckaerts L., Joossens M., Claes K., Van Schuerbeek N., et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:870-878.
11. Hutchings H., Ortega N., Plouet J. Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. Faseb J 2003, 17:1520-1522.
12. Koomagi R., Zintl F., Sauerbrey A., Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 2001, 7:3381-3384.
13. Wellmann S., Guschmann M., Griethe W., Eckert C., von Stackerlberg A., Lottaz C., et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004, 18:926-933.
14. Hood J.D., Meininger C.J., Ziche M., Granger H.J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998, 274:H1054-H1058.
15. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997, 99:2625-2634.
16. Isenberg J.S., Martin-Manso G., Maxhimer J.B., Roberts D.D. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009, 9:182-194.
17. Schwentker A., Vodovotz Y., Weller R., Billiar T.R. Nitric oxide and wound repair: role of cytokines?. Nitric Oxide 2002, 7:1-10.
18. Lambrechts D., Storkebaum E., Morimoto M., Del- Favero J., Desmet F., Marklund SL., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003, 34:383-394.
19. Sandrim V.C., Palei A.C., Luizon M.R., Izidoro-Toledo T.C., Cavalli R.C., Tanus-Santos J.E. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J 2009.
20. Shahbazi M., Fryer A.A., Pravica V., Brojan I.J., Ramsay H.M., Hutchinson I.V., et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002, 13:260-264.
21. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002, 51:1635-1639.
22. Miyamoto Y., Saito Y., Nakayama M., Shimasaki Y., Yoshimura T., Yoshimura M., et al. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T>C mutation associated with coronary spastic angina. Hum Mol Genet 2000, 9:2629-2637.
23. Nakayama M., Yasue H., Yoshimura M., Shimasaki Y., Kugiyama K., Ogawa H., et al. -786T>C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999, 99:2864-2870.
24. Joshi M.S., Mineo C., Shaul P.W., Bauer J.A. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. Faseb J 2007, 21:2655-2663.
25. Casas J.P., Cavalleri G.L., Bautista L.E., Smeeth L., Humphries S.E., Hingorani A.D. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol 2006, 164:921-935.
26. Zhang M.X., Ou H., Shen Y.H., Wang J., Wang J., Coselli J., et al. Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci USA 2005, 102:16967-16972.
27. Krajinovic M., Robaey P., Chiasson S., Lemeiux- Blanchard E., Rouillard M., Primeau M., et al. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 2005, 6:293-302.
28. Scrideli C.A., Assumpcao J.G., Ganazza M.A., Araujo M., Toloedo S.R., Lee M.L., et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica 2009, 94:781-789.
29. Muniz J.J., Izidoro-Toledo T.C., Metzger I.F., Sandrim V.C., Tanus-Santos J.E. Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA Cell Biol 2009, 28:567-572.
30. Marroni A.S., Metzger I.F., Souza-Costa D.C., Nagassaki S., Sandrim V.C., Correa R.X., et al. Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 2005, 12:177-182.
31. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
32. Avramis I.A., Panosyan E.H., Dorey F., Holcenberg J.S., Avramis V.I. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962. Clin Cancer Res 2006, 12:6978-6984.
33. Diao L.P., Yu X.M., Gao Y.H., Li Y., Liu H.S., Liu L.H., et al. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma. J Cancer Res Clin Oncol 2009, 135:1473-1481.
34. Kawai Y., Sakano S., Korenaga Y., Eguchi S., Naito K. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007, 52:1147-1155.
35. Monzo M., Brunet S., Urbano-Ispizua A., Navarro A., Perea G., Esteve J., et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006, 107:4871-4879.
36. Kim D.H., Xu W., Kamel-Reid S., Liu X., Jung C.W., Kim S., et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2009.
37. Metzger I.F., Souza-Costa D.C., Marroni A.S., Nagassaki S., Desta Z., Flockhart D.A., et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 2005, 15:565-570.
38. Lancaster J.R., Xie K. Tumors face NO problems?. Cancer Res 2006, 66:6459-6462.
39. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19:711-721.
40. Shami P.J., Maciag A.E., Eddington J.K., Udupi V., Kosak K.M., Saavedra J.E., et al. JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). Leuk Res 2009, 33:1525-1529.
41. Ghilardi G., Biondi M.L., Cecchini F., DeMonti M., Guagnellini E., Scorza R. Vascular invasion in human breast cancer is correlated to -786T>C polymorphism of NOS3 gene. Nitric Oxide 2003, 9:118-122.
42. Medeiros R., Morais A., Vasconcelos A., Costa S., Pinto D., Oliveira J., et al. Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer. Eur J Cancer Prev 2002, 11:343-350.
43. Hefler L.A., Grimm C., Lantzsch T., Lampe D., Koelbl H., Lebrecht A., et al. Polymorphisms of the endothelial nitric oxide synthase gene in breast cancer. Breast Cancer Res Treat 2006, 98:151-155.
44. Cheon K.T., Choi K.H., Lee H.B., Park S.K., Rhee Y.K., Lee Y.C. Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung 2000, 178:351-360.